BIOMAT Database Logo BIOMAT Database Logo

Combination of selective androgen and estrogen receptor modulators in orchiectomized rats. 2022

P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
Department of Trauma Surgery, Orthopaedics and Plastic Surgery, University of Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. jonathan.roch@med.uni-goettingen.de.

OBJECTIVE Selective androgen and estrogen receptor modulators, ostarine (OST) and raloxifen (RAL), reportedly improve muscle tissue and offer therapeutic approaches to muscle maintenance in the elderly. The present study evaluated the effects of OST and RAL and their combination on musculoskeletal tissue in orchiectomized rats. METHODS Eight-month-old Sprague Dawley rats were analyzed. Experiment I: (1) Untreated non-orchiectomized rats (Non-ORX), (2) untreated orchiectomized rats (ORX), (3) ORX rats treated with OST during weeks 0-18 (OST-P), (4) ORX rats treated with OST during weeks 12-18 (OST-T). Experiment II: 1) Non-ORX, (2) ORX, 3) OST-P, (4) ORX rats treated with RAL, during weeks 0-18 (RAL-P), 5) ORX rats treated with OST + RAL, weeks 0-18 (OST + RAL-P). The average daily doses of OST and RAL were 0.4 and 7 mg/kg body weight (BW). Weight, fiber size, and capillarization of muscles, gene expression, serum markers and the lumbar vertebral body were analyzed. RESULTS OST-P exerted favorable effects on muscle weight, expression of myostatin and insulin growth factor-1, but increased prostate weight. OST-T partially improved muscle parameters, showing less effect on the prostate. RAL-P did not show anabolic effects on muscles but improved body constitution by reducing abdominal area, food intake, and BW. OST + RAL-P had an anabolic impact on muscle, reduced androgenic effect on the prostate, and normalized food intake. OST and RAL improved osteoporotic bone. CONCLUSIONS The OST + RAL treatment appeared to be a promising option in the treatment of androgen-deficient conditions and showed fewer side effects than the respective single treatments.

UI MeSH Term Description Entries
D008297 Male Males
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015519 Bone Density The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS. Bone Mineral Content,Bone Mineral Density,Bone Densities,Bone Mineral Contents,Bone Mineral Densities,Density, Bone,Density, Bone Mineral
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D020845 Selective Estrogen Receptor Modulators A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) Estrogen Receptor Modulators, Selective,SERMs,Estrogen Receptor Modulator, Selective,SERM,Selective Estrogen Receptor Modulator
D020847 Estrogen Receptor Modulators Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure. Antiestrogens,Antiestrogen,Estrogen Receptor Modulator,Modulator, Estrogen Receptor,Modulators, Estrogen Receptor,Receptor Modulator, Estrogen,Receptor Modulators, Estrogen

Related Publications

P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
A combined treatment with selective androgen and estrogen receptor modulators prevents bone loss in orchiectomized rats.
December 2022, Journal of endocrinological investigation,
P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
New selective estrogen and androgen receptor modulators.
July 2009, Current opinion in rheumatology,
P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
Estrogen, selective estrogen receptor modulators and now mechanism-specific ligands of the estrogen or androgen receptor?
June 2003, Trends in pharmacological sciences,
P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
Selective estrogen receptor modulators.
June 2000, IDrugs : the investigational drugs journal,
P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
Selective estrogen-receptor modulators.
May 2003, Clinics in geriatric medicine,
P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
Selective estrogen receptor modulators.
May 2003, Southern medical journal,
P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
Selective estrogen receptor modulators.
September 2002, Reviews in endocrine & metabolic disorders,
P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
Selective estrogen-receptor modulators.
May 2003, The New England journal of medicine,
P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
Selective estrogen receptor modulators.
June 1998, Climacteric : the journal of the International Menopause Society,
P J Roch, and V Wolgast, and M-M Gebhardt, and K O Böker, and D B Hoffmann, and D Saul, and A F Schilling, and S Sehmisch, and M Komrakova
[Selective estrogen receptor modulators].
July 1998, Medizinische Monatsschrift fur Pharmazeuten,
Copied contents to your clipboard!